VolitionRx is developing two types of non-invasive cancer diagnostic tests based on its patented Nucleosomics® technology. The company’s overarching goal is to bring to market its cancer blood tests and revolutionize cancer diagnosis.

While VolitionRx’s current focus is on the detection of colorectal cancer, future plans call for expansion into detection of various other cancers as well. Following ongoing clinical trials and regulatory approval, the company plans to offer its tests for individualized cancers under the NuQ® brand.

Backed by a scientific advisory board comprised of scientists from Europe, Asia, and the United States, VolitionRx is boldly progressing in the development of its cancer test, and in the next year expects to begin to get the results from its ongoing clinical trial involving 16,000 patients.

In the near future, the company also anticipates receiving legal approval to sell its test in Europe, as well as start the process of U.S. FDA trials. Furthermore, VolitionRx looks forward to the second half of the year, at which time management hopes to uplist the company’s stock to a major exchange.

For more information, visit www.volitionrx.com or www.nucleosomics.com

Let us hear your thoughts below: